Automation

MegaRobo Secures $200M for AI Lab Automation Platform

Chinese startup's total funding reaches $600M as it builds infrastructure connecting AI models to physical laboratory equipment.

Omega Editorial · November 19, 2026 · 3 min read

Key takeaways

  • MegaRobo Technologies raised nearly $200 million from Oman Investment Authority, CMB International, and existing investors, bringing total funding to $600 million.
  • The company's One Intelligence Stack connects AI software with laboratory instruments and robotics to automate scientific experiments from planning through analysis.
  • MegaRobo's Megalaxy Lab platform has served more than 200 customers and will test over 10,000 protein sequences through the Poreva Open AI protein-design challenge.
  • The company plans to expand its AI for Science business internationally and extend its technology to other domains requiring AI-physical world interaction.
  • MegaRobo positions itself as building infrastructure for AI systems that learn through physical experimentation rather than static knowledge bases.

MegaRobo raises nearly $200 million for lab automation expansion

China-based MegaRobo Technologies has closed a financing round of nearly $200 million to expand its AI-powered laboratory automation platform and develop technology that bridges AI models with physical equipment.

The round included participation from Oman Investment Authority, the sultanate's sovereign wealth fund, alongside new investor CMB International and existing backers Granite Asia, Sinovation Ventures, and Asia Investment Capital. The financing brings MegaRobo's total capital raised to approximately $600 million, according to the company.

MegaRobo builds systems that allow AI software to control and coordinate laboratory instruments, robotics, and automation equipment. The company's core product, One Intelligence Stack, enables researchers to design experiments, execute them through automated equipment, and analyze results to inform subsequent research cycles. The initial commercial focus targets scientific research and pharmaceutical development, including drug screening and candidate evaluation.

Platform serves pharmaceutical and biotech customers

The company reports that its products and technologies have reached more than 500 customers across pharmaceutical companies, biotechnology firms, and research institutions. Its Megalaxy Lab platform, which allows researchers and AI agents to configure experiments and transmit instructions to automated laboratory equipment, has served more than 200 customers.

MegaRobo plans to deploy the new capital to advance its technology development, expand its AI for Science business into international markets, and build systems capable of working with increasingly complex equipment and physical processes.

The company has partnered with Tencent Cloud and Twist Bioscience to launch Poreva Open, an international AI protein-design challenge. The initiative will use Megalaxy Lab to conduct laboratory testing of more than 10,000 protein sequences, enabling developers to validate their AI-generated designs against experimental outcomes.

Why it matters

MegaRobo's approach addresses a critical bottleneck in AI-driven scientific discovery: translating computational predictions into physical experiments at scale. As pharmaceutical companies and research institutions accelerate adoption of AI for drug discovery and materials science, platforms that automate the feedback loop between digital models and laboratory validation could significantly compress research timelines. The company's expansion beyond scientific research into other domains requiring AI-physical world interaction signals a broader shift toward embodied AI systems that learn through experimentation rather than static datasets.

Building infrastructure for physical AI

Founder and CEO Daniel Huang framed the company's mission as enabling a fundamental transition in artificial intelligence. "The first generation of AI learned from humanity's accumulated knowledge," Huang said in the announcement. "The next generation will increasingly learn by acting in the physical world — through experiments, production and continuous feedback. That shift changes AI from a system that interprets the world into one that can help create new knowledge, materials, processes and products. MegaRobo is building the infrastructure for that transition."

The company indicated it intends to extend its technology beyond scientific research to additional settings where AI systems must interact with machines, materials, and physical processes.

These details were first reported by The AI Insider.

  • #laboratory automation
  • #ai for science
  • #megarobo
  • #drug discovery
  • #embodied ai
  • #robotics

This is an original analysis by the Omega editorial team. Source reporting: Automation Watch.

Want systems like this working for your business?

Book a Call

More in Automation